Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
Gorana Vukorepa
, Sabina Deveđija , Miljenko Crnjaković , Mirna Karakaš , Zeljka Cuk
Department of Neurology, University Hospital Dubrava, Zagreb, Croatia
Keywords: Acute ischemic stroke, acute stroke therapy, anticoagulants, dabigatran, idarucizumab, thrombolysis
Abstract
Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80‐year‐old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA.
How to cite this article: Vukorepa G, Deveđija* S, Crnjaković M, Karakaš M, Cuk Z. Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window. Turk J Emerg Med 2020;20:90-2
GV, SD, MC, MK and ŽĆ managed the patient. GV and SD wrote the draft. All authors revised and approved the final version of the manuscript.
None declared.
None declared.